Long-term Efficacy and Safety Results: Can Enzalutamide Challenge the Dogma of Androgen Deprivation Therapy in Hormone-naïve Prostate Cancer?
Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Sud, Villejuif, France.
Laurence
L
Albiges
Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Sud, Villejuif, France. Electronic address: yohann.loriot@gustaveroussy.fr.
Yohann
Y
Loriot
Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Sud, Villejuif, France.
Christophe
C
Massard
Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Sud, Villejuif, France.
Karim
K
Fizazi
D059002:Androgen Receptor Antagonists / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D001549:Benzamides; D001859:Bone Neoplasms / Q000188:drug therapy*; D000077143:Docetaxel; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000097:blood*; D009570:Nitriles; D010669:Phenylthiohydantoin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy*; D043823:Taxoids / Q000627:therapeutic use*
D059002:Androgen Receptor Antagonists; D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal; D001549:Benzamides; D009570:Nitriles; D043823:Taxoids; D000077143:Docetaxel; D010669:Phenylthiohydantoin; C540278:enzalutamide